scholarly journals Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Susanna Esposito ◽  
Nicola Principi
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Evaluation Studies ◽  
First Year ◽  
Global Evaluation ◽  
Immunization Schedule ◽  
Effective Prevention ◽  
Pneumococcal Carriage ◽  
Pediatric Immunization ◽  
Heptavalent Pneumococcal Conjugate Vaccine

Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A. After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.

scholarly journals Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine Booster in Taiwanese Toddlers

2006 ◽  
Vol 105 (7) ◽  
pp. 542-549 ◽  
Author(s):  
Pei-Lan Shao ◽  
Po-Ren Hsueh ◽  
Chun-Yi Lu ◽  
Luan-Yin Chang ◽  
Fu-Yuan Huang ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Vaccine Booster ◽  
Heptavalent Pneumococcal Conjugate Vaccine

scholarly journals Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster

2010 ◽  
Vol 17 (12) ◽  
pp. 1970-1976 ◽  
Author(s):  
F. M. Russell ◽  
J. R. Carapetis ◽  
C. Satzke ◽  
L. Tikoduadua ◽  
L. Waqatakirewa ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Polysaccharide Vaccine ◽  
Dose Effect ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Pneumococcal Carriage ◽  
Primary Series ◽  
Vaccine Type ◽  
Vaccine Booster ◽  
Antibody Levels

ABSTRACT This study was conducted to evaluate the effect of a reduced-dose 7-valent pneumococcal conjugate vaccine (PCV) primary series followed by a 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster on nasopharyngeal (NP) pneumococcal carriage. For this purpose, Fijian infants aged 6 weeks were randomized to receive 0, 1, 2, or 3 PCV doses. Within each group, half received 23vPPS at 12 months. NP swabs were taken at 6, 9, 12, and 17 months and were cultured for Streptococcus pneumoniae. Isolates were serotyped by multiplex PCR and a reverse line blot assay. There were no significant differences in PCV vaccine type (VT) carriage between the 3- and 2-dose groups at 12 months. NP VT carriage was significantly higher (P, <0.01) in the unvaccinated group than in the 3-dose group at the age of 9 months. There appeared to be a PCV dose effect in the cumulative proportion of infants carrying the VT, with less VT carriage occurring with more doses of PCV. Non-PCV serotype (NVT) carriage rates were similar for all PCV groups. When groups were pooled by receipt or nonreceipt of 23vPPS at 12 months, there were no differences in pneumococcal, VT, or NVT carriage rates between the 2 groups at the age of 17 months. In conclusion, there appeared to be a PCV dose effect on VT carriage, with less VT carriage occurring with more doses of PCV. By the age of 17 months, NVT carriage rates were similar for all groups. 23vPPS had no impact on carriage, despite the substantial boosts in antibody levels.

scholarly journals Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and one year after the introduction of the 13-valent pneumococcal conjugate vaccine

Vaccine ◽  
2019 ◽  
Vol 37 (30) ◽  
pp. 4068-4075 ◽  
Author(s):  
Claire von Mollendorf ◽  
Eileen M. Dunne ◽  
Sophie La Vincente ◽  
Mukhchuluun Ulziibayar ◽  
Bujinlkham Suuri ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Carriage ◽  
One Year

scholarly journals Limited Added Value of Oropharyngeal Swabs for Detecting Pneumococcal Carriage in Adults

2020 ◽  
Vol 7 (9) ◽  
Author(s):  
Jennifer L Farrar ◽  
Herine Odiembo ◽  
Arthur Odoyo ◽  
Godfrey Bigogo ◽  
Lindsay Kim ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Added Value ◽  
Pneumococcal Carriage ◽  
Rural Kenya

Abstract We compared pneumococcal isolation rates and evaluated the benefit of using oropharyngeal (OP) specimens in addition to nasopharyngeal (NP) specimens collected from adults in rural Kenya. Of 846 adults, 52.1% were colonized; pneumococci were detected from both NP and OP specimens in 23.5%, NP only in 22.9%, and OP only in 5.7%. Ten-valent pneumococcal conjugate vaccine strains were detected from both NP and OP in 3.4%, NP only in 4.1%, and OP only in 0.7%. Inclusion of OP swabs increased carriage detection by 5.7%; however, the added cost of collecting and processing OP specimens may justify exclusion from future carriage studies among adults.

Sign in / Sign up

Export Citation Format

Share Document